title: Neutralization of HIV-1 by secretory IgA induced by oral immunization with a new macromolecular multicomponent peptide vaccine candidate.
abstract: Control of pandemic infection of human immunodeficiency virus type 1 (HIV-1) requires some means of developing mucosal immunity against HIV-1 because sexual transmission of the virus occurs mainly through the mucosal tissues. However, there is no evidence as yet that the secretory immunoglobulin A (IgA) antibody induced by immunization with antigens in experimental animals can neutralize HIV-1. We demonstrate here that oral immunization with a new macromolecular peptide antigen and cholera toxin (CT) induces a high titre (1:2") of gut-associated and secretory IgA antibody to HIV-1. Using three different neutralizing assays, we clearly demonstrate that this secretory IgA antibody is able to neutralize HIV-1IIIB, HIV-1SF2 and HIV-1MN. Our new approach may prove to be important in the development of a mucosal vaccine that will provide protection of mucosal surfaces against HIV-1.
authors.affiliation: Department of Oral and Maxillofacial Surgery, Yokohama City University School of Medicine, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Bukawa
authors.forename: K
authors.initials: K
authors.lastname: Sekigawa
authors.forename: K
authors.initials: K
authors.lastname: Hamajima
authors.forename: J
authors.initials: J
authors.lastname: Fukushima
authors.forename: Y
authors.initials: Y
authors.lastname: Yamada
authors.forename: H
authors.initials: H
authors.lastname: Kiyono
authors.forename: K
authors.initials: K
authors.lastname: Okuda
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage / Q000276:immunology*; D000284:Administration, Oral; D000595:Amino Acid Sequence; D000818:Animals; D000918:Antibody Specificity; D001665:Binding Sites; D015704:CD4 Antigens / Q000378:metabolism; D002772:Cholera Toxin / Q000276:immunology*; D016384:Consensus Sequence; D005753:Gastric Mucosa / Q000276:immunology; D015483:HIV Antibodies / Q000096:biosynthesis / Q000276:immunology*; D015699:HIV Envelope Protein gp120 / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D007071:Immunoglobulin A, Secretory / Q000096:biosynthesis / Q000276:immunology*; D007413:Intestinal Mucosa / Q000276:immunology; D007564:Japan; D051379:Mice; D008807:Mice, Inbred BALB C; D008969:Molecular Sequence Data; D009500:Neutralization Tests; D010446:Peptide Fragments / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology*
chemical_list: D016915:AIDS Vaccines; D015704:CD4 Antigens; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; C059762:HIV envelope protein gp120 (305-321); D007071:Immunoglobulin A, Secretory; D010446:Peptide Fragments; D014614:Vaccines, Synthetic; D002772:Cholera Toxin